Filter posts

Fighting Ebola with Tobacco

Years in the making, the Ebola virus has recently erupted into a full blown health …

New study shows hepatitis C burden may ease in future

Anew study published in the Annals of Internal Medicine projects that the prevalence of hepatitis …

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the …

Greenwood Highlights Need for Bold Action to Address Alzheimer's

Last week, Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), participated and …

Treating Hepatitis C: Too Costly Not to Act

Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act …

Partners for Healthy Dialogues: Letter to CMS

BIO, a member of Partners for Healthy Dialogues (P4HD), joined 25 medical societies and manufacturers in …

New Report: Innovation in Hepatitis C Treatment

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis …

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original …

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how …

Jim Greenwood Talks 21st Century Cures with Chairman Fred Upton

Recently, BIO CEO and President Jim Greenwood sat down with House Energy and Commerce Chairman …